90 related articles for article (PubMed ID: 23813934)
1. Imatinib tackles lymphoma via the PDGFRβ+ pericyte.
Chute JP; Himburg HA
Blood; 2013 Jun; 121(26):5107-8. PubMed ID: 23813934
[No Abstract] [Full Text] [Related]
2. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
Ruan J; Luo M; Wang C; Fan L; Yang SN; Cardenas M; Geng H; Leonard JP; Melnick A; Cerchietti L; Hajjar KA
Blood; 2013 Jun; 121(26):5192-202. PubMed ID: 23632889
[TBL] [Abstract][Full Text] [Related]
3. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Lu C; Thaker PH; Lin YG; Spannuth W; Landen CN; Merritt WM; Jennings NB; Langley RR; Gershenson DM; Yancopoulos GD; Ellis LM; Jaffe RB; Coleman RL; Sood AK
Am J Obstet Gynecol; 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
[TBL] [Abstract][Full Text] [Related]
4. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
[TBL] [Abstract][Full Text] [Related]
5. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.
Hosaka K; Yang Y; Seki T; Nakamura M; Andersson P; Rouhi P; Yang X; Jensen L; Lim S; Feng N; Xue Y; Li X; Larsson O; Ohhashi T; Cao Y
Nat Commun; 2013; 4():2129. PubMed ID: 23831851
[TBL] [Abstract][Full Text] [Related]
6. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
7. Screening assay for blood vessel maturation inhibitors.
Fu C; van der Zwan A; Gerber S; Van Den Berg S; No E; Wang WC; Sheibani N; Carducci MA; Kachhap S; Hammers HJ
Biochem Biophys Res Commun; 2013 Aug; 438(2):364-9. PubMed ID: 23892038
[TBL] [Abstract][Full Text] [Related]
8. A differential role for CD248 (Endosialin) in PDGF-mediated skeletal muscle angiogenesis.
Naylor AJ; McGettrick HM; Maynard WD; May P; Barone F; Croft AP; Egginton S; Buckley CD
PLoS One; 2014; 9(9):e107146. PubMed ID: 25243742
[TBL] [Abstract][Full Text] [Related]
9. A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.
Özcetin A; Aigner A; Bakowsky U
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):711-5. PubMed ID: 23891770
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
McCarty MF; Somcio RJ; Stoeltzing O; Wey J; Fan F; Liu W; Bucana C; Ellis LM
J Clin Invest; 2007 Aug; 117(8):2114-22. PubMed ID: 17641778
[TBL] [Abstract][Full Text] [Related]
11. STI-571 inhibits in vitro angiogenesis.
Dudley A; Gilbert RE; Thomas D; Cox A; Price JT; Best J; Jenkins A
Biochem Biophys Res Commun; 2003 Oct; 310(1):135-42. PubMed ID: 14511660
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in cancer and transgenic animal model.
Inui A
Cancer Invest; 2003; 21(5):819-20. PubMed ID: 14628441
[No Abstract] [Full Text] [Related]
13. Bone metabolism during long-term treatment with imatinib.
O'Sullivan S; Horne A; Wattie D; Porteous F; Gamble G; Browett P; Grey A
Leuk Lymphoma; 2013 Aug; 54(8):1783-5. PubMed ID: 23278638
[No Abstract] [Full Text] [Related]
14. [Problems in the current target therapy of malignancies].
Stukov AN; Gershanovich ML; Filov VA; Imianitov EN
Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022
[No Abstract] [Full Text] [Related]
15. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing.
Rajkumar VS; Shiwen X; Bostrom M; Leoni P; Muddle J; Ivarsson M; Gerdin B; Denton CP; Bou-Gharios G; Black CM; Abraham DJ
Am J Pathol; 2006 Dec; 169(6):2254-65. PubMed ID: 17148686
[TBL] [Abstract][Full Text] [Related]
16. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Yener U; Avsar T; Akgün E; Şeker A; Bayri Y; Kılıç T
J Neurosurg; 2012 Oct; 117(4):697-704. PubMed ID: 22900848
[TBL] [Abstract][Full Text] [Related]
17. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.
Pierobon M; Silvestri A; Spira A; Reeder A; Pin E; Banks S; Parasido E; Edmiston K; Liotta L; Petricoin E
J Proteome Res; 2014 Jun; 13(6):2846-55. PubMed ID: 24787230
[TBL] [Abstract][Full Text] [Related]
18. Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2.
Cogle CR
J Natl Cancer Inst; 2013 Mar; 105(6):378-9. PubMed ID: 23446756
[No Abstract] [Full Text] [Related]
19. Korean Red Ginseng Extract Enhances the Anticancer Effects of Imatinib Mesylate Through Abrogation p38 and STAT5 Activation in KBM-5 Cells.
Jung SY; Kim C; Kim WS; Lee SG; Lee JH; Shim BS; Kim SH; Ahn KS; Ahn KS
Phytother Res; 2015 Jul; 29(7):1062-72. PubMed ID: 25857479
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
